19 citations
,
May 2004 in “The American Journal of Dermatopathology”
The research found that a specific gene mutation causes fewer hair follicles and disrupted hair growth cycles, leading to thin and shorthair in people with Hypotrichosis with Juvenile Macular Dystrophy.
PP405 shows promise in stimulating new terminalhair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
A 31-year-old man shares his 4-month hair regrowth progress using topical minoxidil, topical finasteride, microneedling, biotin, and other supplements. He reports new hair growth despite experiencing side effects from finasteride and plans to continue his regimen for further improvement.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
Thin, shorthairs often appear in areas of hair loss but may not grow fully despite treatments like finasteride. Some users consider additional treatments like microneedling or hair transplants.
Considering adding Low Level Laser Therapy (LLLT) to a hair loss prevention regimen; discussing the effectiveness of LLLT, and evaluating double-blind random-controlled trials that have been conducted on laser combs.